Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fatty acid clues: could Mom's placenta hold key to preemie eye disease?

NCT ID NCT04819893

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at why some premature babies develop retinopathy of prematurity (ROP), an eye condition that can affect vision. Researchers think fatty acids from the mother may play a role. They will collect blood, placenta, and cord samples from 135 mothers and their preterm or full-term babies to see how fatty acid receptors in the placenta relate to ROP. The goal is to better understand the biology, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward ways to prevent or better manage retinopathy of prematurity by understanding how fatty acids are transferred from mother to baby.
What could go wrong
This is an observational study focused on understanding mechanisms, not testing a treatment. It is small (135 participants) and early-stage, so results may not lead directly to clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 135 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women giving birth at term or prematurely

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Mothers giving birth to premature babies less than 29 weeks of amenorrhea (WA), after obtaining their non-opposition. 2. Mothers giving birth at term between 39 and 41WA+6 days, after obtaining their non-opposition. 3. ≥18 years 4. Mothers not under legal protection Exclusion Criteria: 1. Mothers giving birth between 29WA and 38WA+6 days 2. Mothers in critical condition. 3. Person not affiliated to national health insurance 4. For full-term mothers: patient presenting or having presented a health condition that affected a previous pregnancy (vascular such as pregnant hypertension, preeclampsia; gestational diabetes; intrauterine growth retardation, maternal infection during pregnancy such as toxoplasmosis, cytomegalovirus, rubella, measles, chickenpox).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prematurity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Premature Birth retinal disorder retinopathy of prematurity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prematurity Retinopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Dijon Bourogne

    RECRUITING

    Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.